Stocks in play: Covalon Technologies Ltd.

Announced that the Company's Board of Directors has approved the grant of an aggregate of 295,000 deferred stock units to certain of its directors and officers. All DSUs were granted pursuant to the Company's omnibus long-term incentive plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange. Covalon Technologies Ltd. shares V.COV are trading unchanged at $1.44.

Read:

• The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

• Canada’s Gold Sector Gaining Boosts from Several Promising Quebec Projects and Mines

• Decoding the Lithium Rush: From Oil Giants to Automakers

• Time Bomb Ticking as Surplus in Carbon Offset Credits on Path Towards Huge Shortage

• Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game